Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Autologous-non-bulbar-dermal-sheath-fibroblast-therapy-RepliCel-Life-Sciences (Primary)
- Indications Photosensitivity; Skin aging
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors RepliCel Life Sciences
- 13 Apr 2017 Results published in a RepliCel Life Sciences media release.
- 04 Apr 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2017.
- 04 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History